Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma

Yoshihiro Komohara; Mamoru Harada; Yoshimi Arima; Shigetaka Suekane; Masanori Noguchi; Akira Yamada; Kyogo Itoh; Kei Matsuoka

doi:10.1016/j.juro.2006.10.035

Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma

Yoshihiro Komohara, Mamoru Harada, Yoshimi Arima, Shigetaka Suekane, Masanori Noguchi, Akira Yamada, Kyogo Itoh, Kei Matsuoka

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24⁺ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24⁺ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3_503-511, multidrug resistance-associated protein 3_1293-1302, polycomb group protein enhancer of zeste homologue 2_291-299, polycomb group protein enhancer of zeste homologue 2_735-743, Her2/neu_342-350 and Her2/neu_485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24⁺ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8⁺ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.

Original language	English
Pages (from-to)	1157-1162
Number of pages	6
Journal	Journal of Urology
Volume	177
Issue number	3
DOIs	https://doi.org/10.1016/j.juro.2006.10.035
Publication status	Published - 2007 Mar
Externally published	Yes

Keywords

T-lymphocytes
cancer vaccines
carcinoma
cytotoxic
kidney
renal cell

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.juro.2006.10.035

Cite this

@article{62669318eb3e4b3f97c1e4e58687afff,

title = "Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma",

abstract = "Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24+ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3503-511, multidrug resistance-associated protein 31293-1302, polycomb group protein enhancer of zeste homologue 2291-299, polycomb group protein enhancer of zeste homologue 2735-743, Her2/neu342-350 and Her2/neu485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8+ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.",

keywords = "T-lymphocytes, cancer vaccines, carcinoma, cytotoxic, kidney, renal cell",

author = "Yoshihiro Komohara and Mamoru Harada and Yoshimi Arima and Shigetaka Suekane and Masanori Noguchi and Akira Yamada and Kyogo Itoh and Kei Matsuoka",

note = "Funding Information: Supported by Grants-in-Aid 16591628 (KM), 16790933 (SS) and 12213134 (KI) from the Ministry of Education, Science, Sports and Culture of Japan, and H14-trans-002, 11-16, H12-cancer-004 (KI) and 15-17 (MH) from the Ministry of Health, Labor and Welfare, Japan. ",

year = "2007",

month = mar,

doi = "10.1016/j.juro.2006.10.035",

language = "English",

volume = "177",

pages = "1157--1162",

journal = "Investigative Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma

AU - Komohara, Yoshihiro

AU - Harada, Mamoru

AU - Arima, Yoshimi

AU - Suekane, Shigetaka

AU - Noguchi, Masanori

AU - Yamada, Akira

AU - Itoh, Kyogo

AU - Matsuoka, Kei

N1 - Funding Information: Supported by Grants-in-Aid 16591628 (KM), 16790933 (SS) and 12213134 (KI) from the Ministry of Education, Science, Sports and Culture of Japan, and H14-trans-002, 11-16, H12-cancer-004 (KI) and 15-17 (MH) from the Ministry of Health, Labor and Welfare, Japan.

PY - 2007/3

Y1 - 2007/3

N2 - Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24+ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3503-511, multidrug resistance-associated protein 31293-1302, polycomb group protein enhancer of zeste homologue 2291-299, polycomb group protein enhancer of zeste homologue 2735-743, Her2/neu342-350 and Her2/neu485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8+ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.

AB - Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24+ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3503-511, multidrug resistance-associated protein 31293-1302, polycomb group protein enhancer of zeste homologue 2291-299, polycomb group protein enhancer of zeste homologue 2735-743, Her2/neu342-350 and Her2/neu485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8+ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.

KW - T-lymphocytes

KW - cancer vaccines

KW - carcinoma

KW - cytotoxic

KW - kidney

KW - renal cell

UR - http://www.scopus.com/inward/record.url?scp=33846817515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846817515&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.10.035

DO - 10.1016/j.juro.2006.10.035

M3 - Article

C2 - 17296437

AN - SCOPUS:33846817515

SN - 0022-5347

VL - 177

SP - 1157

EP - 1162

JO - Investigative Urology

JF - Investigative Urology

IS - 3

ER -

Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this